Nan Fung Trinity HK Ltd. Acquires Shares of 37,642 Scholar Rock Holding Corporation $SRRK

Nan Fung Trinity HK Ltd. bought a new position in shares of Scholar Rock Holding Corporation (NASDAQ:SRRK) in the third quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund bought 37,642 shares of the company’s stock, valued at approximately $1,402,000.

Several other institutional investors and hedge funds also recently made changes to their positions in the business. AlphaQuest LLC boosted its position in shares of Scholar Rock by 30.1% in the 3rd quarter. AlphaQuest LLC now owns 3,415 shares of the company’s stock worth $127,000 after purchasing an additional 791 shares during the last quarter. Federated Hermes Inc. increased its holdings in Scholar Rock by 232.1% in the third quarter. Federated Hermes Inc. now owns 800,455 shares of the company’s stock valued at $29,809,000 after purchasing an additional 559,455 shares during the last quarter. EFG Asset Management North America Corp. lifted its stake in Scholar Rock by 71.2% in the third quarter. EFG Asset Management North America Corp. now owns 88,106 shares of the company’s stock valued at $3,279,000 after buying an additional 36,628 shares during the period. Universal Beteiligungs und Servicegesellschaft mbH lifted its stake in Scholar Rock by 108.2% in the third quarter. Universal Beteiligungs und Servicegesellschaft mbH now owns 159,741 shares of the company’s stock valued at $5,949,000 after buying an additional 83,003 shares during the period. Finally, StoneCrest Wealth Management Inc. bought a new position in Scholar Rock during the third quarter worth about $1,763,000. Institutional investors own 91.08% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of analysts have recently commented on the company. Bank of America started coverage on Scholar Rock in a research note on Thursday, October 9th. They issued a “buy” rating and a $53.00 price target for the company. Truist Financial reduced their target price on Scholar Rock from $54.00 to $44.00 and set a “buy” rating on the stock in a report on Monday, October 20th. JPMorgan Chase & Co. increased their price target on Scholar Rock from $46.00 to $47.00 and gave the stock an “overweight” rating in a report on Tuesday, November 18th. BMO Capital Markets reiterated an “outperform” rating and set a $50.00 price objective on shares of Scholar Rock in a report on Friday, November 14th. Finally, HC Wainwright increased their target price on Scholar Rock from $44.00 to $58.00 and gave the stock a “buy” rating in a research note on Monday. Four analysts have rated the stock with a Strong Buy rating, twelve have assigned a Buy rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat, Scholar Rock presently has a consensus rating of “Buy” and an average price target of $51.14.

Insiders Place Their Bets

In other Scholar Rock news, COO Keith Woods sold 16,746 shares of Scholar Rock stock in a transaction on Tuesday, January 13th. The shares were sold at an average price of $42.70, for a total value of $715,054.20. Following the sale, the chief operating officer directly owned 583,254 shares in the company, valued at approximately $24,904,945.80. The trade was a 2.79% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Also, insider Mo Qatanani sold 136,462 shares of the business’s stock in a transaction dated Thursday, December 4th. The stock was sold at an average price of $45.21, for a total transaction of $6,169,447.02. Following the sale, the insider directly owned 108,964 shares in the company, valued at $4,926,262.44. This trade represents a 55.60% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Insiders have sold 305,687 shares of company stock valued at $13,540,573 in the last quarter. Company insiders own 13.30% of the company’s stock.

Scholar Rock Stock Down 1.3%

SRRK stock opened at $44.34 on Friday. The company has a debt-to-equity ratio of 0.41, a current ratio of 6.30 and a quick ratio of 6.30. The stock has a market capitalization of $4.52 billion, a P/E ratio of -14.08 and a beta of 0.63. Scholar Rock Holding Corporation has a fifty-two week low of $22.71 and a fifty-two week high of $48.28. The business has a 50-day moving average of $44.27 and a 200-day moving average of $37.55.

Scholar Rock (NASDAQ:SRRK) last released its earnings results on Friday, November 14th. The company reported ($0.90) EPS for the quarter, missing the consensus estimate of ($0.88) by ($0.02). During the same quarter in the previous year, the company posted ($0.66) earnings per share. On average, sell-side analysts anticipate that Scholar Rock Holding Corporation will post -2.42 earnings per share for the current fiscal year.

Scholar Rock Profile

Scholar Rock is a clinical-stage biotechnology company focused on the discovery and development of protein therapeutics that selectively target growth factors involved in disease processes. The company’s research platform is designed to modulate endogenous growth factor activation and signaling with high specificity, aiming to restore normal biological function across a range of disorders. Scholar Rock’s approach is distinguished by its emphasis on engineering antibodies and biologics that interact with growth factor precursors or latent complexes rather than the active form, potentially offering improved safety and efficacy profiles.

The company’s lead program, SRK-015 (appercept), is an investigational monoclonal antibody targeting the activation of latent myostatin proproteins and is being evaluated for the treatment of spinal muscular atrophy (SMA).